Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs Abstract #2794

Introduction: Several classes of antibiotics have been associated with anti-proliferative effects on cancer cells; however, there is no data on this regarding pNETs.
Aim(s): To report an interesting case suggesting potential anti-tumor effects of antibiotics in pNET.
Materials and methods: A 44 year-old male patient presented with a pancreatic lesion and hepatic masses suspicious for metastasized pancreatic cancer. Liver biopsy revealed a NET G2 (Ki67 7%) with immunohistochemistry compatible with the pancreatic primary. Gallium-68-DOTANOC PET/CT confirmed somatostatin-receptor (SSR) positive disease. In August 2018, lanreotide 120 mg q4 weeks was started. Subsequent controls showed stable disease, but a scan performed after 11 months of treatment revealed new cavernous lung lesions without SSR expression suggestive for tuberculosis. PCR of the sputum was positive for mycobacteria. In view of attested rifampicin-resistance, a multi-drug-resistant antibiotic regimen including levofloxacin, linezolid, terizidone, clofazimine and amikacin (switched to ethambutol) was initiated. The treatment lasted for 8 weeks but was finally stopped due to the lack of further positive cultures.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD Barbara Kiesewetter

To read results and conclusion, please login ...

Further abstracts you may be interested in

#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Philippe Ruszniewski
Keywords: PRO
#980 ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Somatostatin analogs (SSAs) are the mainstay treatment
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Edda Gomez-Panzani
Keywords: symptom control
#1303 Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals
Introduction: Lanreotide depot (LAN) was recently approved by the FDA to treat mGEP-NETs to improve progression-free survival.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: George Camba
Authors: Ortendahl J, Pulgar S, Cox D, Bentley T, ...
#1538 Safety of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
Introduction: Dose escalation (or interval reduction) of somatostatin analogs (SSAs) is a rather common strategy for patients (pts) with progressive metastatic neuroendocrine tumors (NETs). However, to date, no systematic prospective studies have been carried out to evaluate safety and efficacy of this treatment schedule in NETs.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD, PhD Manuela Albertelli
#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD, PhD Manuela Albertelli
Keywords: SSA high dose